Improving oral bioavailability of acalabrutinib using polymer-lipid hybrid nanoparticles: design, optimization, and in vivo pharmacokinetic evaluation
{{output}}
Acalabrutinib (ACP) is one of the first-in-line treatments for hematological malignancies with minimal adverse drug reactions. However, ACP has low and variable bioavailability due to pH-dependent solubility, CYP3A4 metabolism, and P-gp efflux. This research a... ...
